Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Gilead and partner Galapagos no longer will pursue clinical trials in the United States with filgotinib in rheumatoid arthritis and other conditions, but still could pursue the drug as a treatment for inflammatory bowel disease.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Arthritis | Biotechnology | Clinical Trials | Health Management | Inflammatory Bowel Disease | Rheumatoid Arthritis | Rheumatology | USA Health